about
Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issuesComparative QSAR analyses of competitive CYP2C9 inhibitors using three-dimensional molecular descriptors.Recent updates on glucokinase activators for the treatment of type 2 diabetes mellitus.Hybrid poly(lactic-co-glycolic acid) nanoparticles: design and delivery prospectives.Green synthesis of therapeutic nanoparticles: an expanding horizon.A facile green approach to prepare core-shell hybrid PLGA nanoparticles for resveratrol delivery.Diverse models for anti-HIV activity of purine nucleoside analogs.Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel.Predicting acyl-coenzyme A: cholesterol O-acyltransferase inhibitory activity: computational approach using topological descriptors.Quantitative structure-activity relationship models with receptor-dependent descriptors for predicting peroxisome proliferator-activated receptor activities of thiazolidinedione and oxazolidinedione derivatives.Stability indicating simplified HPLC method for simultaneous analysis of resveratrol and quercetin in nanoparticles and human plasma.Mesoporous silica nanoparticles: a smart nanosystem for management of breast cancer.Synthesis, Docking and Anti-Inflammatory Activity of Triazole Amine Derivatives as Potential Phosphodiesterase-4 Inhibitors.Design, synthesis and biological evaluation of novel thiazol-2-yl benzamide derivatives as glucokinase activators.N-Pyridin-2-yl Benzamide Analogues as Allosteric Activators of Glucokinase: Design, Synthesis, In Vitro, In Silico and In Vivo EvaluationTopological model for the prediction of MRP1 inhibitory activity of pyrrolopyrimidines and templates derived from pyrrolopyrimidineTopological models for the prediction of anti-HIV activity of dihydro (alkylthio) (naphthylmethyl) oxopyrimidinesEvaluation of polyamidoamine dendrimers as potential carriers for quercetin, a versatile flavonoidDesign, synthesis and evaluation of novel 3,5-disubstituted benzamide derivatives as allosteric glucokinase activators
P50
Q26825175-E12E78BE-4C80-42D4-B4DE-5618664821E2Q30401651-28CD255E-F7BC-43CF-BBCD-400E31F31E47Q38232768-C5EA8CB5-4BE8-4D4A-BFD6-AFA324D67C36Q38256209-AA6E0F0B-DA60-4BCA-8A7A-7D6FD442689DQ38557961-4C29EACA-910C-49D0-AFD6-37CD7B963BC1Q38808694-C58F8105-28DA-476C-AC56-A91AFE66013EQ41178917-727C4E2A-5839-40E5-968B-93C53FBCB201Q41988569-8126CC57-227B-4261-915E-60130804F020Q45156251-336E2B1F-2B22-4C56-A06F-A69662B6C9B3Q46109138-BBF431A5-CD9E-4EB2-BFDE-BE1B56D3F153Q47894391-5AAC15FF-419C-41B8-A2A3-4B48ED1CCADAQ50057616-79782D14-CE89-457A-BE54-9A15BD153B92Q50942655-1DF3ABC5-4CB7-4691-9EEF-B9E7FDC29F56Q52666519-7AE6E8A9-B8A3-497B-AA81-A9BAE88C334FQ58108226-1000E85C-0922-4562-AD1A-57D4DFBA29B7Q81228611-8004E0E4-7E71-4543-984C-0B4759C10C57Q81377273-97EE5701-F2FC-484F-8550-2FC57FB2CE77Q87914553-C11FE70D-A312-4130-AA23-3570DD368E91Q92437580-29FDCC32-7FC6-43E9-A819-0A3B474B97D0
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Viney Lather
@en
Viney Lather
@nl
type
label
Viney Lather
@en
Viney Lather
@nl
prefLabel
Viney Lather
@en
Viney Lather
@nl
P31
P496
0000-0002-7323-3142